Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2021 07:30 ET | Source: Graybug Vision, Inc.

Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
December 17, 2020 08:00 ET | Source: CalciMedica

CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Blinded placebo-controlled trial is expected to enroll more than 100 patients at U.S. clinical sites by end of DecemberThe Company expects to complete enrollment of the trial by the end of Q1 2021 LA...
November 16, 2020 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference

REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
November 13, 2020 08:00 ET | Source: CalciMedica

CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke

First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of strokeCRAC channel inhibitors represent an important future potential...
November 12, 2020 16:05 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
November 05, 2020 08:00 ET | Source: CalciMedica

CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer

Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc....
September 25, 2020 08:00 ET | Source: Graybug Vision, Inc.

Graybug Appoints Three New Members to its Board of Directors

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
September 24, 2020 20:12 ET | Source: Graybug Vision, Inc.

Graybug Vision Announces Pricing of Upsized Initial Public Offering

REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
September 04, 2020 07:00 ET | Source: Graybug Vision, Inc.

Graybug Vision Appoints Robert Breuil as Chief Financial Officer

REDWOOD CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
August 18, 2020 08:00 ET | Source: CalciMedica

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right